Oncolys BioPharma Inc. (4588.T)
JPY 602.0
(-1.79%)
JPY 602.0
(-1.79%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 63.03 Million JPY | -93.54% |
| 2022 | 976.18 Million JPY | 51.94% |
| 2021 | 642.49 Million JPY | 104.5% |
| 2020 | 314.17 Million JPY | -75.9% |
| 2019 | 1.3 Billion JPY | 673.57% |
| 2018 | 168.54 Million JPY | -26.44% |
| 2017 | 229.13 Million JPY | 28.5% |
| 2016 | 178.31 Million JPY | 47.0% |
| 2015 | 121.3 Million JPY | 321.23% |
| 2014 | 28.79 Million JPY | 2340.42% |
| 2013 | 1.18 Million JPY | -99.7% |
| 2012 | 396.75 Million JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | - JPY | 0.0% |
| 2024 Q2 | 31.38 Million JPY | 0.0% |
| 2023 Q4 | - JPY | 0.0% |
| 2023 FY | 63.03 Million JPY | -93.54% |
| 2023 Q1 | 35 Million JPY | -81.74% |
| 2023 Q2 | 28.03 Million JPY | -19.89% |
| 2023 Q3 | - JPY | -100.0% |
| 2022 FY | 976.18 Million JPY | 51.94% |
| 2022 Q2 | 233.02 Million JPY | 20.66% |
| 2022 Q1 | 193.12 Million JPY | -40.43% |
| 2022 Q4 | 191.67 Million JPY | -46.51% |
| 2022 Q3 | 358.35 Million JPY | 53.78% |
| 2021 Q3 | 125.25 Million JPY | -4.0% |
| 2021 Q4 | 324.17 Million JPY | 158.82% |
| 2021 Q1 | 62.6 Million JPY | -41.26% |
| 2021 Q2 | 130.46 Million JPY | 108.4% |
| 2021 FY | 642.49 Million JPY | 104.5% |
| 2020 Q3 | 71.49 Million JPY | 8.59% |
| 2020 Q4 | 106.56 Million JPY | 49.05% |
| 2020 FY | 314.17 Million JPY | -75.9% |
| 2020 Q2 | 65.84 Million JPY | -6.31% |
| 2020 Q1 | 70.27 Million JPY | -89.41% |
| 2019 FY | 1.3 Billion JPY | 673.57% |
| 2019 Q1 | 48.38 Million JPY | -3.48% |
| 2019 Q3 | 19.1 Million JPY | -96.66% |
| 2019 Q2 | 572.62 Million JPY | 1083.52% |
| 2019 Q4 | 663.73 Million JPY | 3374.13% |
| 2018 Q3 | 27.97 Million JPY | -50.55% |
| 2018 Q4 | 50.12 Million JPY | 79.17% |
| 2018 Q2 | 56.57 Million JPY | 67.0% |
| 2018 FY | 168.54 Million JPY | -26.44% |
| 2018 Q1 | 33.87 Million JPY | -83.07% |
| 2017 Q4 | 200.11 Million JPY | 2093.49% |
| 2017 FY | 229.13 Million JPY | 28.5% |
| 2017 Q1 | 15.38 Million JPY | -88.33% |
| 2017 Q2 | 4.52 Million JPY | -70.59% |
| 2017 Q3 | 9.12 Million JPY | 101.66% |
| 2016 Q4 | 131.77 Million JPY | 6984.57% |
| 2016 Q3 | 1.86 Million JPY | -87.7% |
| 2016 Q1 | 29.56 Million JPY | -70.84% |
| 2016 FY | 178.31 Million JPY | 47.0% |
| 2016 Q2 | 15.12 Million JPY | -48.85% |
| 2015 Q1 | 2.14 Million JPY | -90.1% |
| 2015 FY | 121.3 Million JPY | 321.23% |
| 2015 Q4 | 101.36 Million JPY | 742.91% |
| 2015 Q3 | 12.02 Million JPY | 108.68% |
| 2015 Q2 | 5.76 Million JPY | 168.55% |
| 2014 FY | 28.79 Million JPY | 2340.42% |
| 2014 Q2 | 1.86 Million JPY | -20.38% |
| 2014 Q3 | 2.92 Million JPY | 56.9% |
| 2014 Q4 | 21.67 Million JPY | 641.4% |
| 2014 Q1 | 2.34 Million JPY | 105.26% |
| 2013 FY | 1.18 Million JPY | -99.7% |
| 2013 Q4 | 1.14 Million JPY | 0.0% |
| 2012 FY | 396.75 Million JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 4.77 Billion JPY | 98.678% |
| PRISM BioLab Co.,LTD | 112.92 Million JPY | 44.178% |
| GNI Group Ltd. | 26.01 Billion JPY | 99.758% |
| Linical Co., Ltd. | 12.3 Billion JPY | 99.488% |
| Trans Genic Inc. | 13.08 Billion JPY | 99.518% |
| MEDINET Co., Ltd. | 661.54 Million JPY | 90.471% |
| Soiken Holdings Inc. | 5.15 Billion JPY | 98.778% |
| Cytori Cell Research Institute, Inc. | 1.56 Billion JPY | 95.96% |
| AnGes, Inc. | 152.98 Million JPY | 58.795% |
| OncoTherapy Science, Inc. | 610.11 Million JPY | 89.668% |
| Nxera Pharma Co., Ltd. | 12.76 Billion JPY | 99.506% |
| Immuno-Biological Laboratories Co., Ltd. | 816.7 Million JPY | 92.281% |
| NanoCarrier Co., Ltd. | 135.5 Million JPY | 53.48% |
| Carna Biosciences, Inc. | 1.62 Billion JPY | 96.123% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 428.36 Million JPY | 85.284% |
| RaQualia Pharma Inc. | 1.9 Billion JPY | 96.684% |
| Chiome Bioscience Inc. | 682.46 Million JPY | 90.763% |
| Kidswell Bio Corporation | 2.43 Billion JPY | 97.407% |
| PeptiDream Inc. | 28.71 Billion JPY | 99.78% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | 121 Million JPY | 47.902% |
| BrightPath Biotherapeutics Co., Ltd. | 72 Thousand JPY | -87452.778% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 39.88 Million JPY | -58.041% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 4.51 Billion JPY | 98.602% |
| FunPep Company Limited | 530 Thousand JPY | -11793.962% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 8.97% |
| Stella Pharma Corporation | 269.49 Million JPY | 76.608% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | 316.81 Million JPY | 80.103% |
| Cuorips Inc. | 23.1 Million JPY | -172.868% |
| K Pharma,Inc. | 1 Billion JPY | 93.696% |
| Takara Bio Inc. | 43.5 Billion JPY | 99.855% |
| ReproCELL Incorporated | 2.42 Billion JPY | 97.402% |
| PhoenixBio Co., Ltd. | 1.71 Billion JPY | 96.325% |
| StemCell Institute Inc. | 2.48 Billion JPY | 97.459% |
| Japan Tissue Engineering Co., Ltd. | 2.51 Billion JPY | 97.493% |
| CellSeed Inc. | 190.13 Million JPY | 66.845% |